Despite all their shortcomings, the truth is human beings remain pretty much limitless in what they can achieve. This fact isn’t lost on us; therefore we are always trying to aim for that next big thing. It’s not to say we have had success on every single occasion, but even our failures have left us a tad smarter than we were before. Now, like anyone would guess, when you have such a progressive dynamic pulling all the strings, it has to deliver some outright ingenious by-products over time. Nevertheless, if we look back for a second, we’ll easily notice how none of them match up with technology. Technology emerges as the clear winner here due to factors that aren’t just about guiding us in one way or the other. Instead, they talk at length to a revolution, which the creation started right after arriving on the scene. This would quickly transition into a reality where our entire spectrum had technology as the ultimate centerpiece. It was the case for a very good reason, and to affirm that with evidence, we only have to look at the creation’s impact on a sector like healthcare. As soon as we instilled new-age tech principles in the healthcare fabric, things around the block changed rather dramatically. Suddenly, all the wrongs we used to associate with the sector were gone. In fact, one recent funding indicates that healthcare is still going strong upon what has proven to be a picture-altering trajectory.
Nutcracker Therapeutics, a company best known for its unique take on mRNA medicines, has officially secured over $167 million from a recently-concluded Series C round. According to certain reports, the round was exclusively led by ARCH Venture Partners, who also led the company’s $60 million Series B round in 2020. Following the fresh cash injection, however, Nutcracker plans on developing its drug pipeline, and it will do the same through an approach like no other. You see, the company’s core method is interestingly based upon combining biochemistry with advanced biochips. Throw in a super-efficient nanoparticle delivery technology as well, and you have enough manufacturing prowess to completely reinvent the manner and speed at which therapeutics can be discovered and developed.
“The recent success of the mRNA vaccines for COVID-19 has brought newfound energy around the use of RNA as a therapeutic tool,” said Igor Khandros, co-founder and CEO of Nutcracker Therapeutics. “As a consequence, we have an unparalleled opportunity to bring this emerging class of medicines to treat patients suffering from very complex diseases.”
Apart from raising the floor of therapeutic production, Nutcracker’s fully-automated system is also designed to scale up as per the therapy’s progress. With the said flexibility, it is able to address the need of different stages like discovery, clinical testing, and commercialization. If all the pieces fall right, Nutcracker believes that its technology has the potential to make a significant cutback on the cost and cycle times of mRNA therapeutic development.
While the company has refused to give any details regarding its drug pipeline, it did hint towards focusing on cancer treatment.
